<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

Flow Cytometry - Driving CAR T Cell Therapy from Bench to Bedside

Posted on: June 27, 2018


Chimeric antigen receptor (CAR) T cell therapy is transforming patient-specific cancer treatment, even for the most challenging forms of cancer. CAR T cells are made by isolating a patient’s T cells from the blood and engineering them in the lab so that they can specifically fight the patient’s cancer. This custom-made biologic is both time and labor-intensive and extremely costly, but it is also an extremely effective form of treatment.

Check out the top four ways flow cytometry is an indispensable tool for CAR T cell therapy

Scientist testing blood samples1. Basic Research: Decades of basic research have brought CAR T cells to clinical trials and beyond, and flow cytometry has been a critical tool in evaluating how to optimize the effectiveness of different CAR T cell products. Much work has gone into engineering CARs with effective T cell receptor and co-stimulatory components that enhance tumor-fighting abilities and preserve the long-term persistence of CAR T cells in a patient’s circulation.

2. T Cell Isolation: CAR T cell products must be made with a patient’s own T cells, and leukapheresis is used to isolate these cells from patients while returning all other blood components to their circulation. Flow cytometry analysis of isolated blood products assures that a sufficient number of healthy and functional T cells are used for processing and re-infusion.

3. CAR T Cell Preparation: Different genetic engineering tools are used to transfer the instructions for the multifunctional CARs into a patient’s T cells. Flow cytometry is used in quality assurance/quality control (QA/QC) protocols to assure that a sufficient number of viable T cells are expressing CAR, and makes sure that these cells show other phenotypic indicators of T cell functionality.

4. Clinical Immune Monitoring: CAR T cell products that meet the appropriate QA/QC criteria can be reinfused into patients. Validated flow cytometry protocols are used to monitor the persistence and functionality of these cells as the effectiveness of this treatment is evaluated.

New call-to-action

Posted in: ,

Click me